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Abstract
Background: Epidemiological studies have established human papillomavirus (HPV) infection as the central cause
of invasive cervical cancer (ICC) and its precursor lesions. HIV is associated with a higher prevalence and persistence
of a broader range of high-risk HPV genotypes, which in turn results in a higher risk of cervical disease. Recent
WHO HPV vaccination schedule recommendations, along with the roll out of HAART at an earlier CD4 count within
the female HIV-infected population, may have programmatic implications for sub Saharan Africa. This
communication identifies research areas, which will need to be addressed for determining a HPV vaccine schedule
for this population in sub Saharan Africa. A review of WHO latest recommendations and the evidence concerning
one-dose HPV vaccine schedules was undertaken.
Conclusion: For females ≥15 years at the time of first dose and immunocompromised and/or HIV-infected, a
3-dose schedule (0, 1–2, 6 months) is recommended for all three vaccines. There is some evidence that there is
similar protection against HPV 16 and 18 infection from a single vaccination than from two or three doses, however
there is no cross protection conferred to other genotypes. There is a need for periodic prevalence studies to
determine the vaccination coverage of bivalent, quadrivalent and nonavalent vaccine targeted oncogenic HPV
genotypes in women with CIN 3 or ICC at national level. In light of the increasing number of sub Saharan HIV-
infected girls initiating HAART at a CD4 count above 350 mm3, there are a number of clinical, virological and public
health research gaps to address before a tailored vaccine schedule can be established for this population.
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Background
Cervical cancer is the fourth most common malignancy
with 528,000 new cases reported worldwide in 2015 [1]. In
resource-poor countries, delayed diagnosis often makes
cure impossible. Forty HPV genotypes have been identi-
fied, of which 14 high risk types (HR-HPV) are associated
with the development of high-grade precancerous squa-
mous intraepithelial lesions and subsequent invasive cer-
vical cancer (ICC) [2]. Although most HPV infections
clear without intervention within 1 year, certain high-risk
HPV (HR-HPV) genotypes tend to persist and are conse-
quently the chief risk factor for ICC onset [3].
Several sub Saharan countries have licensed and
adopted the bivalent HPV vaccine (Cervarix™) that pro-
tects against HPV genotypes 16 and 18 and the quadri-
valent vaccine (Gardasil™) that protects against HPV
genotypes 6, 11, 16 and 18 [4]. The bivalent and quadri-
valent prophylactic vaccine, which contain the genotypes
responsible for about 70% of cervical cancers globally,
constitute a breakthrough for primary prevention. Fur-
thermore, the bivalent HPV vaccine offers substantial
cross protection against HPV genotypes 31/33/45 as
demonstrated in both clinical trials and confirmed in
Scottish HPV surveillance study [5]. A new nonavalent
vaccine containing HPV types, containing the most
prevalent genotypes found in ICC worldwide 6, 11, 16,
18, 31, 33, 45, 52 and 58 [6] may have direct
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implications for cervical cancer incidence and preven-
tion potentially preventing almost 90% of ICC cases
worldwide [7]. The WHO recommends including the
HPV vaccination in national immunization programs
provided HPV represents a public health priority and
vaccination is feasible and cost-effective [8].
HIV-positive women are particularly at risk for HPV
infection and precancerous lesions, for whom, lesions
are more aggressive, persistent and more likely to recur
following treatment [9]. In primary cervical cancer pre-
vention, there is another potentially effective weapon.
Our recent systematic review of HAART effects on the
presence of HPV, pre-malignant and malignant cervical
lesions in Sub-Saharan Africa found evidence that dur-
ation of HAART, along with the CD4 count, may reduce
the prevalence of HR-HPV [10].
This communication paper identifies research gaps for
determining a vaccine schedule for HIV-infected girls in
sub Saharan Africa. We explored WHO policy papers
and guidelines concerning HPV vaccination schedules
and examined the evidence for a one-dose regimen.
Main text
Target group and vaccination schedule
For the bivalent, quadrivalent and nonavalent vaccines,
the vaccination schedule depends on the age and immu-
nocompetency of the recipient. Girls < 15 years at the
time of first dose: a 2-dose schedule (0, 6 months) is rec-
ommended. The two doses should ideally be separated
by 6 to 12 months and the interval from the first dose
should not be less than 5 months [11]. For women aged
15 years and older, and those immunocompromised
and/or HIV-infected, receiving HAART or not, a 3-dose
schedule (0, 1–2, 6 months) is recommended [11].
Whilst, studies have shown the bivalent, quadrivalent
and nonavalent to be safe and immunogenic in
HIV-infected women [12] with women with HIV RNA
load > 10,000 copies/ml and or CD4 count < 200 cells
having lower rates of seroconversion rates, there is to
date no efficacy data from HIV-infected individuals in
Sub Saharan Africa. Nor is the duration of adequate
antibody titers to the vaccine associated HPV types
established, which precludes a boosting vaccine dosing
regimen from being established. A specific aspect to
consider within the sub Saharan continent, where hel-
minths are among the major public health problems
[13], is the resultant dominant Th2 helper immune re-
sponse [14]. In turn a dominant Th2 helper immune re-
sponse may further diminish the necessary Th1 response
in HIV infected female and as corollary, modify the po-
tency of the vaccine [15].
Moreover, with HAART initiation at a higher CD4
count, seroprevalence studies should consider whether
HIV-infected girls (9–14 years), who have initiated
HAART at a CD4 count above 350 mm3 are immuno-
logically non-inferior to immunocompetent girls having
been administered the recommended two-dose schedule
recommended for the bivalent, quadrivalent, and nona-
valent HPV vaccine in that age group.
The impact of the bivalent or quadrivalent vaccine in
the HIV-infected female population in sub-Saharan Af-
rica will depend on the prevalence of HPV 16 and HPV
18. A recent meta-analysis (2016) on the distribution of
pHR/HR HPV genotypes in HIV-infected women in
Kenya reported a pooled estimated prevalence of HPV
16 and 18 of 61% in women with ICC [16], in presence
of multiple HPV co-infections. Whilst HPV-16 and
HPV-18 pose much higher cancer risks than any other
HPV type and replacement by a nononcogenic type or
an oncogenic type is not expected to have any major
consequences in a general population [17], it is unclear
what this shift in a HIV-infected population may entail.
Given the wide spectrum of HPV genotypes reported in
HIV-infected women, the threat of type replacement
[18] by hitherto less prevalent HPV genotypes, including
HPV 52, 56 along with the potentially high risk of HPV
53 after the successful elimination of HPV 16 and 18,
underscores the importance of broader primary preven-
tion programs.
One-dose schedule
A study combining data from two large trials found
similar protection against HPV 16 and 18 from a single
bivalent vaccination as from the current two and three
dose schedules [19]. Moreover, early findings from an
Indian study indicate that a single dose of quadrivalent
HPV vaccine is immunogenic and provides lasting pro-
tection against HPV 16 and 18 infections similar to the
three and two dose vaccine schedules [20].
Apart from helping to overcome programmatic bar-
riers in resource-poor settings, if HPV vaccines could be
delivered as single dose, while retaining their efficacy
against the most oncogenic HPV types 16 and 18, it may
open a great opportunity to extend the reach of protec-
tion to more people [21].
However, protection against HPV types
phylogenetically-related to HPV 16, HPV 31 and 33, and
against HPV45, which is phylogenetically-related to HPV
18, probably attributable to cross-neutralizing antibodies,
may be lower with alternate vaccine schedule as compared
with the standard three dose regimen [22]. Despite the po-
tential loss of cross-protection, a single dose may be suffi-
cient to reduce the number of ICC worldwide by 70%
[23]. It is unknown whether a one-dose HPV vaccination
schedule can confer similar protection to HIV-infected
women with a moderately reconstituted immune system.
Should studies suggest that similar protection can be ex-
tended to women with moderately reconstituted immune
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systems, cost-effectiveness analyses must be undertaken to
compare a one dose regimen to a two/three-dose vaccine
regimen in HIV-infected girls/women based on the epi-
demiology of pHR/HR HPV genotypes within each
context.
Catch-up campaigns
In 2016, the WHO revised its position to recommend
delivering vaccination to multiple age cohorts of girls
aged 9–14 years in resource-poor settings in order to in-
crease HPV vaccine uptake and bring forward the bene-
fits of vaccination in the population [24], following the
rapid effectiveness seen in many industrialized countries
where HPV vaccine introduction has been extended to
the age of 26.
Assuming affordable vaccine cost and knowledge of
the local distribution of HPV genotypes, additional
catch-up rounds may be beneficial to older HIV-infected
girls, whose future access to cervical screening is uncer-
tain and who are at risk of acquiring and transmitting
multiple HPV co-infections. It has to be recognised,
though, that vaccination campaigns are not meant to re-
place routine immunisation services if sufficient cover-
age is to be maintained [25] and that as female school
enrolment in many countries drops after primary school,
a school-based vaccination strategy may not be success-
ful in capturing older vulnerable HIV-infected girls.
However, it is unclear whether, among women infected
with HPV, the residual benefit of preventing infection
with HPV types contained in the vaccine to which the
women have not yet been exposed would be sufficient to
warrant vaccination [26]. The lesser impact expected of
the HPV vaccine in older HIV-infected women due to a
potential higher risk of prior exposure to vaccine tar-
geted genotypes, may be compensated by the potential
of the HPV vaccine to prevent recurrence of CIN 2–3
among women treated for HSIL [27], possibly due to
generated antibodies providing protection against new
infection or reinfection from other areas of the genital
tract with vaccine targeted types. Estimates for the inci-
dence of disease recurrence after treatment vary widely
from 25 to 55% at 12 months in HIV-infected women
compared with 5–16% in HIV-negative women [28].
Prior to the implementation of a catch-up campaign, a
cost-effectiveness study should be performed. This
would entail comparing the number of cases of HSIL
and cancer, with the associated costs of treatment and
lives/quality of life lost, that would occur with screening
alone, single cohort vaccination only, or single cohort
plus catch up vaccination.
Conclusion
The nonavalent vaccine may provide an incremental
benefit beyond the current bivalent and quadrivalent
vaccines, but in light of their current prohibitive prices,
it will need to be determined whether resources should
be allocated toward vaccinating more girls with either
the bivalent or quadrivalent vaccine. In order to deter-
mine the potential cost effectiveness of the more expen-
sive nonavalent vaccine within sub-Saharan countries,
regular prevalence studies should be carried out to as-
sess the vaccination coverage of bivalent, quadrivalent
and nonavalent vaccine targeted oncogenic HPV geno-
types in women with CIN 3 or ICC at national level. In
addition, the cancer genesis potential of HPV genotypes
excluded by the bivalent/quadrivalent vaccines will need
to be elucidated in women who initiate HAART at a
higher CD4 count. Furthermore, the potential of the
HPV vaccines to prevent CIN 2/3 recurrence in
HIV-infected women should be urgently examined.
Apart from determining the effectiveness of the HPV
vaccine in sub Saharan HIV-infected women with a
reconstituted immune system and concomitant polypar-
asitic infections, in light of the high prevalence of
non-HPV 16 and 18 within this population, surveillance
should be strengthened to monitor the risk of type
replacement.
As in sub Saharan African, it is mostly rural women
who present with ICC, a catch-up campaign should con-
sider adopting a clinic-based vaccination strategy, one
which would be based on an established infrastructure
of rural HIV treatment program.
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